Patents by Inventor Eleftherios Diamandis
Eleftherios Diamandis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070178114Abstract: The invention relates to nucleic acid molecules, proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecule.Type: ApplicationFiled: March 29, 2007Publication date: August 2, 2007Applicant: Mount Sinai HospitalInventors: George Yousef, Eleftherios Diamandis
-
Publication number: 20060269971Abstract: The invention relates to the application of kallikrein 11, free PSA, and total PSA in the detection of prostate cancer. These markers may be used for the diagnosis, monitoring, staging, progression, prevention, treatment, and prognosis of prostate cancer, and as indicators before surgery or after relapse. A particular aspect of the invention provides a method for distinguishing prostate cancer from benign prostatic hyperplasia (BPH).Type: ApplicationFiled: September 26, 2003Publication date: November 30, 2006Applicant: Mount Sinai HospitalInventor: Eleftherios Diamandis
-
Publication number: 20060223059Abstract: Kallikrein 12, kallikrein 14, and kallikrein 15 proteins, and nucleic acids encoding the proteins have particular application in the detection of endocrine cancer, in particular ovarian cancer. Kallikrein 12, kallikrein 14, and kallikrein 15 proteins and nucleic acid molecules encoding the proteins constitute new biomarkers for diagnosis and monitoring (i.e. monitoring progression or therapeutic treatment) of endocrine cancer.Type: ApplicationFiled: September 26, 2003Publication date: October 5, 2006Applicant: Mount Sinai HospitalInventors: George Yousef, Eleftherios Diamandis
-
Publication number: 20060141471Abstract: Methods for diagnosing and monitoring renal cell carcinoma in a subject comprising detecting kallikrein polypeptides, or polynucleotides encoding the polypeptides in a sample from the subject. The kallikrein polypeptides include kallikrein 5, kallirekin 6, kallikrein 10, and kallikrein 11.Type: ApplicationFiled: February 26, 2004Publication date: June 29, 2006Applicant: Mount Sinai HospitalInventors: Eleftherios Diamandis, Constantina Petraki
-
Publication number: 20060134114Abstract: The invention relates to nucleic acid molecules, kallikrein-like proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecules.Type: ApplicationFiled: December 28, 2005Publication date: June 22, 2006Applicant: Mt. Sinai HospitalInventors: George Yousef, Eleftherios Diamandis
-
Publication number: 20060134120Abstract: Methods for diagnosing and monitoring ovarian cancer in a subject comprising measuring a plurality of kallikrein polypeptides, and optionally CA125, or nucleic acids encoding the polypeptides in a sample from the subject. The kallikrein polypeptides include kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11.Type: ApplicationFiled: February 26, 2004Publication date: June 22, 2006Applicant: Mount Sinai HospitalInventor: Eleftherios Diamandis
-
Publication number: 20060073525Abstract: Kallikrein 5 constitutes a novel biomarker for diagnosis, treatment and monitoring of breast and ovarian cancer. A method is provided for diagnosing and monitoring breast or ovarian cancer or a predisposition to breast or ovarian cancer, in a subject comprising detecting kallikrein 5 in a sample from the subject. Imaging methods, screening methods for test agents for inhibiting breast or ovarian cancer, and therapeutic applications based on kallikrein 5 are also described.Type: ApplicationFiled: August 28, 2003Publication date: April 6, 2006Applicant: Mount Sinai HospitalInventors: George Yousef, Eleftherios Diamandis
-
Publication number: 20050287528Abstract: A method for detecting a kallikrein 8 polypeptide associated with ovarian cancer in a patient is provided comprising detecting kallikrein 8 polypeptide in a sample from the patient. Methods are also provided for monitoring the progression of ovarian cancer in a patient, determining whether ovarian cancer has metastasized or is likely to metastasize in the future, and assessing the aggressiveness or indolence of ovarian cancer. In addition, methods for assessing the potential efficacy of a test agent for inhibiting ovarian cancer in a patient, selecting an agent for inhibiting ovarian cancer in a patient, and assessing the ovarian cancer cell carcinogenic potential of a test compound are described. The invention also contemplates a method of treating a patient susceptible to, or having a cancer that expresses a kallikrein 8 polypeptide.Type: ApplicationFiled: April 4, 2003Publication date: December 29, 2005Applicant: Mount Sinai HospitalInventors: Eleftherios Diamandis, Tadaaki Kishi
-
Publication number: 20050176002Abstract: Methods for diagnosing and monitoring ovarian carcinoma in a subject are described comprising measuring KLK9 or hK9 in a sample from the subject. The invention also provides localization or imaging methods for ovarian cancer, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for ovarian cancer employing hK9 proteins, nucleic acid and molecules encoding the proteins, and/or binding agents for the proteins.Type: ApplicationFiled: October 16, 2002Publication date: August 11, 2005Applicant: MOUNT SINAI HOSPITALInventors: Eleftherios Diamandis, George Yousef
-
Publication number: 20050106586Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating neurodegenerative diseases. In particular, the invention utilizes kallikrein 7 and kallikrein 10 and nucleic acids encoding same, to detect, characterize, prevent and treat neurodegenerative diseases.Type: ApplicationFiled: June 14, 2004Publication date: May 19, 2005Applicant: MOUNT SINAI HOSPITALInventor: Eleftherios Diamandis
-
Publication number: 20040203012Abstract: A method for the diagnosis, prognosis, and monitoring of ovarian or prostate cancer in a subject by detecting hK11 in a sample from the subject, preferably a serum sample. hK11 may be measured using a reagent that detects or binds to hK11 preferably antibodies specifically reactive with hK11 or a part thereof. Imaging methods for tumors associated with hK11 are also described using an agent that binds to hK11 which has a label for imaging the tumor.Type: ApplicationFiled: May 21, 2004Publication date: October 14, 2004Inventor: Eleftherios Diamandis
-
Publication number: 20020110862Abstract: The invention relates to nucleic acid molecules, proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecules.Type: ApplicationFiled: October 5, 2001Publication date: August 15, 2002Inventors: George Foussias, Eleftherios Diamandis
-
Publication number: 20020106735Abstract: The invention relates to nucleic acid molecules, proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecules.Type: ApplicationFiled: September 14, 2001Publication date: August 8, 2002Inventors: Andreas Scorilas, Eleftherios Diamandis
-
Publication number: 20020106738Abstract: The invention relates to nucleic acid molecules, proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecules.Type: ApplicationFiled: October 5, 2001Publication date: August 8, 2002Inventors: George Foussias, Eleftherios Diamandis
-
Patent number: 6261766Abstract: This invention relates to the detection of prostate-specific antigen (PSA) in female breast tumor extract as a prognostic or predictive indicator for breast carcinoma. The presence of prostate-specific antigen in breast tumours is associated with earlier disease stage, younger women and better survival. PSA is associated with tumors which have estrogen and/or progersterone receptors.Type: GrantFiled: September 26, 2000Date of Patent: July 17, 2001Assignee: Nordion International, Inc.Inventor: Eleftherios Diamandis
-
Patent number: 6071726Abstract: Rapid and cost effective diagnosis of p53 mutations of a sample of patients is achieved by employing a selected plurality of diagnostic tools, in a hierarchy of increasing accuracy and cost per tool, in which each tool detects essentially no false positives. Diagnostic tests that may be included among the plurality of tests selected include, in order of increasing accuracy and cost:(a) immunoassays,(b) analysis of DNA from a patient sample by quantitative amplification of p53 exons using amplification primers complementary to intron regions flanking each exon and examination of the length or quantity of each amplified fragment for nucleotide insertions or deletions relative to the normal p53 gene.Type: GrantFiled: December 27, 1996Date of Patent: June 6, 2000Assignee: Visible Genetics Inc.Inventors: Eleftherios Diamandis, James M. Dunn, John K. Stevens
-
Patent number: 5723302Abstract: This invention relates to the detection of prostate-specific antigen (PSA) subfractions in serum as a prognostic or predictive indicator for breast carcinoma. In particular this invention relates to an in vitro blood test for the diagnosis of breast cancer using serum PSA subfractions. Serum PSA subfractions are remarkably different in the serum from breast cancer patients, normal male patients and female patients treated for breast cancer.Type: GrantFiled: February 27, 1996Date of Patent: March 3, 1998Assignee: Nordion International Inc.Inventor: Eleftherios Diamandis
-
Patent number: 5552283Abstract: Rapid and cost effective diagnosis of p53 mutations of a sample of patients is achieved by employing a selected plurality of diagnostic tools, in a hierarchy of increasing accuracy and cost per tool, in which each tool detects essentially no false positives. Diagnostic tests that may be included among the plurality of tests selected include, in order of increasing accuracy and cost:(a) immunoassays,(b) analysis of DNA from a patient sample by quantitative amplification of p53 exons using amplification primers complementary to intron regions flanking each exon and examination of the length or quantity of each amplified fragment for nucleotide insertions or deletions relative to the normal p53 gene.Type: GrantFiled: February 14, 1995Date of Patent: September 3, 1996Assignee: Visible Genetics Inc.Inventors: Eleftherios Diamandis, James M. Dunn, John K. Stevens